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Abstract
Background: BAP1 is a histone deubiquitinase that acts as a tumor and metastasis suppressor associated with
disease progression in human cancer. We have used the “Calling Card System” of transposase-directed transposon
insertion mapping to identify the genomic targets of BAP1 in uveal melanoma (UM). This system was developed to
identify the genomic loci visited by transcription factors that bind directly to DNA; our study is the first use of the
system with a chromatin-remodeling factor that binds to histones but does not interact directly with DNA.
Methods: The transposase piggyBac (PBase) was fused to BAP1 and expressed in OCM-1A UM cells. The insertion of
transposons near BAP1 binding sites in UM cells were identified by genomic sequencing. We also examined RNA
expression in the same OCM-1A UM cells after BAP1 depletion to identify BAP1 binding sites associated with BAP1-
responsive genes. Sets of significant genes were analyzed for common pathways, transcription factor binding sites,
and ability to identify molecular tumor classes.
Results: We found a strong correlation between multiple calling-card transposon insertions targeted by BAP1-PBase
and BAP1-responsive expression of adjacent genes. BAP1-bound genomic loci showed narrow distributions of
insertions and were near transcription start sites, consistent with recruitment of BAP1 to these sites by specific DNA-
binding proteins. Sequence consensus analysis of BAP1-bound sites showed enrichment of motifs specific for YY1,
NRF1 and Ets transcription factors, which have been shown to interact with BAP1 in other cell types. Further, a
subset of the BAP1 genomic target genes was able to discriminate aggressive tumors in published gene expression
data from primary UM tumors.
Conclusions: The calling card methodology works equally well for chromatin regulatory factors that do not interact
directly with DNA as for transcription factors. This technique has generated a new and expanded list of BAP1 targets in
UM that provides important insight into metastasis pathways and identifies novel potential therapeutic targets.
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Background
BAP1 is a histone deubiquitinase that remodels chro-
matin to regulate gene expression. The BAP1 polypep-
tide is the catalytic subunit of the polycomb-repressive
deubiquitinase complex, which requires either ASXL1
or ASXL2 [1], and which can include HCFC1, OGT
and other factors [2]. This complex, a component of
the polycomb pathway, removes mono-ubiquitin from
histone H2A [1]. The HCFC1 subunit is a transcrip-
tional co-activator that can bind transcription factors
such as E2F, YY1, and Ets-related transcription factors
[3, 4]; however, its role in targeting BAP1 to chromatin
has not been fully elucidated.
Melanomas arising from the pigmented layers (uvea)
of the eye are highly aggressive cancers: almost half of
patients with uveal melanoma (UM) die from meta-
static disease, even after the primary tumor is com-
pletely removed by surgical excision of the eye [5],
because we are unable to prevent or treat metastatic
spread of the cancer [5]. UMs can be divided into two
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classes by molecular and genetic analysis of the tumor.
Class 1 UMs have a favorable prognosis; the cancers
are low-grade, indolent, and rarely metastasize. Class 2
UMs have a dismal prognosis; they are high-grade, ag-
gressive and nearly always metastasize [6]. Over 95% of
class 2 UMs show complete loss of expression of BAP1
protein [7], with inactivating somatic mutations in the
BAP1 gene in 80% of these tumors [8]. Loss of BAP1
causes UM cells to assume a rounded, epithelioid
morphology, to deposit distinctive extracellular matrix
materials, and to grow well under clonogenic condi-
tions [9, 10], and BAP1-depleted UM cells display in-
creased diapedesis through endothelial monolayers in
a cell-culture model of transendothelial migration [11],
which may reflect their ability to metastasize. BAP1
mutations have been found in other aggressive can-
cers, including skin-derived melanomas, mesothelio-
mas, and renal cell carcinomas [12–17], suggesting a
general role for BAP1 as a suppressor of metastasis in
cancer.
Transposon integration by targeted transposases has
been used to identify genomic regions in several con-
texts [18]. The coordinates and numbers of insertions of
transposons reflect the locations where the factor binds
and the proportion of time the factor is bound to the
locus. The “calling card” methodology fuses a piggyBac
transposase to a protein of interest [19], and uses mul-
tiple bar-coded transposon donor plasmids to improve
the spatial and temporal demarcation of integration sites
[20]. Here, we modified the technique, originally devel-
oped for DNA-binding transcription factors, to detect
the interactions of chromatin with BAP1 complex, which
does not bind directly to DNA. Our results provide
novel insights into the biology of BAP1 in cancer tumor
suppression and metastasis.
Methods
Cell culture and reagents
The coding region of human BAP1 cDNA (NM_004656.2)
from pReceiver-M12 BAP1 (GeneCopoeia, Rockville,
MD) was fused to cDNA encoding the hyperactive pig-
gyBac transposase derived from a pCMV-hyPBase plas-
mid, generously provided by Dr. Allan Bradley [21].
Both N-terminal and C-terminal fusions were prepared,
using Gibson assembly [22]. For BAP1-PBase, BAP1
was placed at the 5′ end of hyPBase with an 18-aa
linker, KLGGGAPAVGGGPKAADK. For PBase-BAP1,
BAP1 was placed at the 3′ end of hyPBase, with the
same linker. Plasmid clones were maintained and ex-
panded in DH5-α cells in carbenicillin, and the iden-
tities of plasmids were confirmed by DNA sequencing
of all regions that underwent PCR amplification (Gene-
wiz; South Plainfield, NJ). Forty uniquely bar-coded
piggyBac transposon plasmids [20] were used as donors
for the calling card protocol. The 40 plasmids were di-
vided into four sets of 10 donors per experiment.
OCM-1A cells were originally derived by Dr. June
Kan-Mitchell [23]. Cells were cultured in growth
medium: RPMI 1640 with 10% FBS and penicillin/
streptomycin (Gibco; Carlsbad, CA) at 37 °C in 5% CO2.
Cells were transfected using TransIT-LT1 transfection
reagent (Mirus; Madison, WI) according to manufac-
turer’s instructions. After 24 h, the medium was replaced
with growth medium containing 1.4 μg/mL puromycin.
Cells were maintained under selection for 2 weeks, at
which point large visible colonies were formed. Colonies
were harvested by trypsinization and centrifugation, and
cell pellets were stored at − 80 °C.
Preparation of genomic DNA
The following procedure was adapted and modified
from [19]. Genomic DNA was isolated from cell pel-
lets using a High MW Cell DNA Isolation Kit (EZ
Bioresearch, St. Louis, MO) according to manufac-
turer instructions. For each sample, three independent
digests were performed with Taq1, Msp1, and CviQ
(New England Biolabs, Ipswich, MA) using 20 μg of
genomic DNA and following manufacturer protocols.
Each separate digested genomic DNA sample was
purified using a Qiaquick PCR Purification Kit (Qia-
gen), self-ligated with T4 Ligase (New England Bio-
labs) at 15 °C for 18–24 h, and purified with Amicon
Ultra-0.5 mL Centrifugal 30 k filters (Millipore; Biller-
ica, MA) with 5-min spins (instead of the standard
protocol of 10–30 min). The circularized genomic
material from the three independent digests were
pooled for each experimental sample and inverse PCR
was performed using piggyBac transposon-specific
primers. DNA fragments from 200 to 1000 bp were
isolated and yields were quantified by UV absorbance.
Next-gen sequencing was performed on the MiSeq
2 × 250 (Illumina) by the Center for Genomic Sci-
ences and Systems Biology at Washington University
in St. Louis, using the transposon-specific sequencing
primer.
Calling card data analysis
Raw reads were mapped back to the human genome
(hg19) with Bowtie2. Significant Calling Cards peaks
were called with a modified version of the previously
described algorithm [19]. Briefly, transposon inser-
tions were clustered into peaks with a maximum dis-
tance of 5 kb between insertions. Significant peaks
were identified using the Poisson distribution to test
for enrichment over the background (unfused trans-
posase) Calling Card data. The expected number of
hops per TTAA was locally estimated from the back-
ground Calling Card data by considering regions
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centered directly under the Calling Card peak, 1 kb
from the Calling Card peak, or 5 kb from the Call-
ing Card peak, and taking the maximum of the three
estimated parameters. Peaks were annotated with
nearby gene information using bedtools.
Lentiviral shRNA knockdown of BAP1
The following was modified from Mooren et al. [24].
Lentiviral pLKO.1 shRNA plasmid targeting BAP1
(NM_004656.2-2658s1c1) was designed by the RNAi
consortium (TRC) and obtained from the Children’s Dis-
covery Institute / Genome Sequencing Center at Wash-
ington University. Lentiviral shRNA expression plasmids
were cotransfected into HEK293T cells with the plas-
mids pCMV-dR8.2 dvpr and pCMV-VSV-G. After 72 h,
viral particles were harvested. OCM-1A cells were in-
fected with lentivirus in growth medium with 8 μg/mL
protamine sulfate. After 24 h, medium was changed to
fresh growth medium containing 1.4 μg/mL puromycin.
OCM-1A cells were harvested for analysis of protein
and RNA 6 days post infection.
RNA sequencing and analysis
RNA was isolated using the Qiagen RNeasy Mini Kit ac-
cording to manufacturer instructions, including the op-
tional DNase I step. Second-strand cDNA synthesis was
performed using SuperScript IV (ThermoFisher Scien-
tific; Waltham, MA) according to manufacturer instruc-
tions. Next-gen RNA sequencing was performed on the
Illumina HiSeq2500 1 × 50 by the Genome Technology
Access Center (Washington University). Three biological
replicates for BAP1 and control (GFP) knockdowns were
sequenced. RNA-Seq analysis was performed by the
Genomic Technology Access Center at Washington Uni-
versity. Reads were aligned to the Ensembl release 76
top-level assembly with STAR version 2.0.4b. Gene
counts were derived from the number of uniquely
aligned unambiguous reads by Subread:featureCount
version 1.4.5. Transcript counts were produced by Sail-
fish version 0.6.3. Sequencing performance was assessed
for total number of aligned reads, total number of
uniquely aligned reads, genes and transcripts detected,
ribosomal fraction known junction saturation and read
distribution over known gene models with RSeQC ver-
sion 2.3.
Gene-level and transcript counts were imported into
the R/Bioconductor package. EdgeR and TMM
normalization size factors were calculated to adjust for
samples with differences in library size. Genes or tran-
scripts not expressed in any sample were excluded
from further analysis. The TMM size factors and the
matrix of counts were imported into R/Bioconductor
package Limma. Weighted likelihoods based on the
observed mean-variance relationship of every gene/
transcript and sample were calculated for all samples
with the voomWithQualityWeights function. General-
ized linear models were then created to test for gene/
transcript level differential expression. Differentially
expressed genes and transcripts were then filtered for
FDR adjusted p-values less than or equal to 0.01. Gene
ontology (GO) and pathway analyses was performed
using Gene Set Enrichment Analysis (GSEA) [25]. GO
groups were assembled by merging the lists of genes
from related GO terms that were significantly
enriched in the signature gene set. GSEA was also
used to identify published molecular signatures (cu-
rated by the Broad Institute: http://broadinstitute.org/
GSEA) that showed significant overlap (p < 0.001) with
response to BAP1 depletion.
DNA motif analysis
BAP1-PBase calling card peaks with five or more inser-
tions were used for Hypergeometric Optimization of
Motif EnRichment (HOMER) analysis (available at:
http://homer.ucsd.edu). Peaks were analyzed separately
depending on whether they were associated with genes
showing significant change (p < 0.01) in expression after
BAP1 depletion, and whether the associated gene in-
creased or decreased expression upon Bap1 depletion.
HOMER was used to identify enriched motifs in gen-
omic regions (findMotifsGenome.pl) using the given size
of each peak.
Results
The calling card system identifies genomic regions bound
by BAP1
We fused the piggyBac transposase (PBase) to BAP1
with a flexible 18-aa linker at either end of BAP1 (Fig. 1).
Each fusion construct was cotransfected with PB donor
plasmids into OCM-1A UM cells; unfused PBase served
as a negative control. Next-gen sequencing of genomic
DNA revealed specific clusters of genomic reads associ-
ated with BAP1-PBase fusion constructs and not present
in control samples. The BAP1-PBase and PBase-BAP1
fusion constructs produced 199,209 and 179,244 gen-
omic transposon insertions, respectively, and these inser-
tion sites clustered into 7,810 (see Additional file 1) and
7,634 (see Additional file 2) genomic peaks. Peaks were
called by accounting for background hops (i.e. a call re-
quired enrichment of BAP1 hops over background).
Only a small subset of genomic peaks showed directly
overlapping insertion peaks with both fusion constructs
(Fig. 2a). For each construct, many genes were found to
contained multiple, non-overlapping peaks. We clus-
tered the genomic peaks based on closest gene (5,883
for BAP1-PBase and 5,542 for PBase-BAP1), and the tar-
geted genes showed substantial overlap (47% for
BAP1-PBase and 50% for PBase-BAP1; Fig. 2b). The
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BAP1-PBase fusion generated more high-number inser-
tion sites than did the PBase-BAP1 fusion, with higher
maximum numbers of transposons per locus (86 for
BAP1-PBase vs. 58 for PBase-BAP1).
BAP1 interacts with chromatin near transcription start
sites
Many genomic peaks with high numbers of insertions
were narrow and centered close to transcription start
sites. The distances of each BAP1-PBase or PBase-BAP1
genomic peak to the nearest transcription start site were
determined and plotted as histograms (Fig. 3). As a con-
trol, we analyzed distances from transcription start sites
for randomly selected regions of the genome (Fig. 3).
Mann-Whitney U tests revealed that BAP1-PBase and
PBase-BAP1 peaks were both significantly closer to tran-
scription start sites (p < 0.0001 for both). One concern
was that PBase alone might be predisposed to target
transposons to open chromatin and thus near active
transcription start sites. Comparing BAP1-fusion inser-
tions with all background insertions, we found distances
to transcription start sites as highly enriched for both fu-
sions (p < 0.0001, Mann-Whitney U tests). Thus, BAP1
binds specifically near transcription start sites.
BAP1 genomic targets show BAP1-dependent gene
expression
To ascertain whether genes targeted by BAP1 in the call-
ing card analysis were functionally regulated by BAP1,
we performed RNA-Seq on OCM-1A cells depleted of
BAP1 by lentiviral shRNAs targeting BAP1. GFP-target-
ing shRNAs served as a negative control [10]. BAP1 pro-
tein levels decreased by 68–74%, compared to GFP
controls, by immunoblot (see Additional file 3). BAP1
transcript levels decreased similarly, to 75%, compared to
controls based on RNA-seq (see Additional file 4). RNA--
Seq results revealed a significant response for 70%
(3,565 / 5,033) of BAP1-targeted genes with > 5 inser-
tions. Among the significant gene targets, 22% (784 /
3,565) exhibited greater than two-fold changes in ex-
pression in response to BAP1 depletion (Fig. 4a-b and
(Additional file 5)). Genes with five or fewer inser-
tions did not show a significant association with ex-
pression changes (Fisher’s exact test, p > 0.01; Fig.
4a). This level of concordance between genomic insertion
and expression change is remarkable. By comparison, a
study of multiple transcription factors found that less than
15% of transcription factor-bound target genes were per-
turbed upon knockdown of the transcription factor [26].
We performed pathway and gene ontology analyses on
the 784 genes identified by the combination of > 2-fold
BAP1-sensitive RNA expression changes and calling-
card transposon targeting. The top three pathways
enriched for the 244 up-regulated targets were the
Fig. 1 Schematic representation of experimental approach. The
calling card system was used to identify regions of genomic interactions
by BAP1. Plasmids were constructed to express BAP1 fused with
the piggyBac transposase (PBase) via an 18-aa linker. After
plasmid transfection into UM cells, expressed BAP1-PBase fusion
proteins interact with nucleosomes containing ubiquitylated histone
H2A via BAP1, allowing PBase to insert a barcoded transposon from a
co-transfected donor plasmid into the adjacent genomic DNA. The
genome is fragmented, and barcoded transposon primers are used to
amplify the genomic insertion sites for each transposon. Next-gen
sequencing is performed to identify the genomic insertion sites, which
are mapped back to the hg38 human genome assemble
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HIF1α, β3-integrin signaling, and p53 signaling pathways
(see Additional file 6). The top three pathways enriched
for the 540 down-regulated targets were the Gαi (G-pro-
tein), PDGF-Rβ signaling, and the EGFR signaling path-
ways (see Additional file 6). Gene ontology analysis
identified significant differential regulation of ontologies
associated with development and differentiation, and
with the cytoskeleton (Fig. 4c). BAP1-depletion was as-
sociated with up-regulation of genes involved in tran-
scription, translation, and protein regulation (Fig. 4c),
and down-regulation of genes involved in vesicular
transport, membrane formation, and cell projections
(Fig. 4c). Two highly significant (p < 0.001) molecular sig-
natures were identified by Gene Set Enrichment Analysis
of BAP1 calling-card target genes associated with gene ex-
pression response to BAP1 depletion (see Additional file 7):
an Epithelial-to-Mesenchymal Transition (EMT) signature
was associated with up-regulated genes; and a polycomb-
mediated lysine27-trimethylation of histone H3 in Embry-
onic Stem Cells was associated with down-regulated genes
(Fig. 4d). These analyses suggest that, in UM cells, BAP1
coordinates several downstream pathways through its
genomic targets that are important to metastatic spread
and survival by regulating differentiation, lineage specifi-
city and stemness.
BAP1 is recruited to specific DNA-binding motifs
Our data suggested recruitment of BAP1 to specific
genes by DNA-binding proteins, as opposed to random
scanning for monoubiquitylated histones. Genomic loci
associated with genes that were up-regulated versus
down-regulated in response to BAP1 depletion were
Fig. 2 BAP1 N-terminal and C-terminal PBase fusions identified overlapping sets of target genes. a Genomic peak regions of transposon
insertions were identified for N-terminal (BAP1-PBase) and C-terminal (PBase-BAP1) fusion constructs. Left: Venn diagram showing modest overlap
of called peaks between the two constructs. Right: representative genomic region illustrating overlapping peaks. b Genes containing or adjacent
to transposon insertion peaks were identified and compared between the two fusion constructs. Left: Venn diagram showing overlap of targeted
genes. Right: representative genomic region showing a gene with non-overlapping insertion peaks. c Differences in the insertion rates between
the two fusion constructs. The number of genomic loci (Y-axis) is plotted against the numbers of insertions per locus (X-axis). A large proportion
of calling card insertions were unclustered background represented by genomic loci with 5 or fewer insertions within 10 kb. PBase-BAP1
produced proportionally fewer genomic loci with multiple insertions than did BAP1-PBase
Yen et al. BMC Medical Genomics           (2018) 11:97 Page 5 of 11
analyzed separately (see Additional file 8). HOMER ana-
lysis is designed for use with large data sets (~ 10,000
peaks), so de novo motif analysis could not be performed
due to the small number of peaks in each data set
(approximately 500–600) being analyzed. Enrichment was
found for a number of motifs bound by transcription fac-
tors that have been previously identified to form com-
plexes with BAP1 [4], including NRF1, Ets factors, and
Fig. 3 BAP1-directed transposon insertions cluster at narrow peaks near transcription start sites. Histograms showing the distance from each BAP1-
PBase or PBase-BAP1 peak to the nearest transcription start site (top and middle panels), or the distance from randomly selected position of the
genome to the nearest transcription start site (bottom panel). Both fusion constructs produced significantly more insertions within 5 kb of transcription
start sites (p < 0.001)
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Fig. 4 Loci with calling card insertions are associated with BAP1-regulated genes. a Correlation of gene expression with genomic loci calling-card
insertions. For genomic loci with > 5 insertions, a statistically significant fraction show changes in expression, based on RNA-Seq, following loss of
BAP1. b Venn diagram showing the overlap between BAP1 target genes > 5 calling-card insertion peaks and genes for which expression changed
significantly (p < 0.01) following BAP1 depletion, as assessed by RNA-Seq. c Gene ontology pathway analysis was performed on BAP1 target genes
divided into sets that were up-regulated or down-regulated in response to BAP1 depletion. Only significant pathways are shown (p < 0.01). d Two
highly significant (p < 0.001) molecular signatures were identified by Gene Set Enrichment Analysis of BAP1 calling-card target genes associated with
gene expression response to BAP1 depletion: the Epithelial-to-Mesenchymal Transition (EMT) signature was associated with up-regulated genes; and
the polycomb-mediated lysine27-trimethylation of histone H3 in Embryonic Stem Cells was associated with down-regulated genes
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YY1. Surprisingly, the up- and down-regulated gene sets
were both enriched for NRF1 and YY1 suggesting that
other transcription factors on the same promoters are de-
termining direction and magnitude of change in gene ex-
pression. On the other hand, only up-regulated genes
were enriched for Ets factor binding sites, suggesting the
existence of a BAP1-containing co-activator complex spe-
cifically associated with Ets-factors.
BAP1 calling card targets are linked to the metastatic
signature
UM tumors are classified clinically by gene expression
profiling of primary tumor samples [6, 27, 28]. We
cross-referenced our list of 784 highly significant BAP1
genomic target genes to the list of genes from primary
tumor expression analysis [6]. We used comparative
marker selection to cluster the genes based on tumor class
to determine whether BAP1-responsive genomic target
genes correlated with the phenotypic distinction between
class 1 and class 2 tumors, (Fig. 5a) (see Additional file 9).
We found that a subset of BAP1 targets were able to dis-
criminate molecular class in primary tumors, so we per-
formed unsupervised principal component analysis on the
patient sample gene expression data using only genes
identified by our analysis as BAP1 genomic targets. This
identified a subset of 79 genes able to differentiate class 1
from class 2 tumors with clear discrimination of the
tumors into two distinct groups (Fig. 5b). Enrichment
analysis of these genes identified targets of ETS2, NF1,
E2F4, and ELK1 in the discriminators that were upreg-
ulated in Class 2 tumors, and targets of FOXO4,
CHX10, and SOX9 in the downregulated discriminators
(see Additional file 10). These genes represent a direct
link between the genomic function of BAP1 and the
metastatic gene expression signature associated with
BAP1 loss in UM tumors.
Discussion
Calling card methodology and chromatin modifying
factors
The calling card methodology identifies genomic locali-
zations of transcription factors that bind DNA directly
[19]. We show that this novel approach can also identify
genomic loci occupied by a chromatin-remodeling fac-
tor, BAP1, which does not bind to DNA directly. We
found that fusions of BAP1 with transposase at either
the N-terminus and C-terminus did not impair transpo-
sase function, and that while a substantial number (32%)
of the genes were identified by both the N-terminal and
C-terminal fusion constructs, the majority were identi-
fied by only one (Fig. 2b). By combining the lists of
Fig. 5 BAP1 calling-card target genes distinguish molecular class in primary UM tumors. Gene expression values from published microarray data
of primary UM tumors [6] were analyzed for genes identified in this study as having BAP1-targeted insertions and significant gene expression
response to BAP1 depletion. a Heatmap showing relative gene expression (blue to red) of BAP1 targets in primary UM tumors. Each column is
one human tumor. Each row is one gene. Genes were clustered by comparative marker selection based on tumor class (see Additional file 9).
Maximum and minimum values were normalized for each row and do not represent global maxima or minima. Black bars indicate genes with
significant differential expression (p < 0.01). b Unsupervised principal component analysis of published tumor data using only BAP1 calling card
targets shows a portion of genes (principal component 2: PC2) that distinguish class 1 (blue circles) from class 2 (red circles) tumors
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results from the two fusions, we generated a substan-
tially larger number of statistically significant genomic
loci, which may provide an important insight for future
calling card studies of chromatin-remodeling factors.
Genomic recruitment of BAP1 to regulate metastasis and
differentiation
Upregulated BAP1-sensitive genes were associated with
motif enrichment for Ets factors including ELF1, which
has been shown previously in other cell types to
co-precipitates with BAP1 [4]. Motifs found in both
up-regulated and down-regulated data sets included
NRF1 (nuclear respiratory factor 1) and YY1 (yin yang
factor 1). NRF1 regulates metabolism, proteasome deg-
radation, and mitochondrial biogenesis [29], and like
ELF1, NRF1 has been shown previously in other cell
types to co-precipitates with BAP1 [4], YY1 also co-pre-
cipitates with BAP1 [4], and YY1 regulates development,
cell cycling, tumorigenesis, cell death, and a number of
other pathways [30]. We suggest that recruitment of
BAP1 by NRF1 and YY1 to specific genes requires the
co-recruitment of tissue and lineage specific transcription
factors to drive the aggressive nature of class 2 UM tumors.
We found pathways related to Epithelial-to-Mesen-
chymal Transition (EMT) and embryonic stem cell
differentiation affected by depletion of BAP1 in UM
cells. Prior studies of gene expression in response to
loss of BAP1 have been performed in two other cell
types, which showed substantial differences from each
other, suggesting that the targets of BAP1 vary de-
pending on cell lineage. In melanocytic cells, BAP1 is
important for expression of genes involved in melano-
blast and neural crest differentiation [10]. In contrast,
in hematopoietic cells, loss of BAP1 affected pathways
related to hematopoietic differentiation [31]. Although
45% of these genes were also targets of BAP1 binding
in UM cells (35% of calling card genes were in the
ChIP-Seq list), none of the hematopoietic differenti-
ation genes responded to BAP1 depletion in our UM
cells. In human non-small cell lung carcinoma cells
(H1299 cells) [32], BAP1 depletion negatively regulated
the FoxK2-target genes MCM3, CDC14a, and CDKN1B.
Although two of these (MCM3 and CDC14a) were targets
of BAP1 binding in UM cells, we found no significant re-
sponse in gene expression to BAP1 depletion. Taken to-
gether, these observations suggest that BAP1’s role in
differentiation depends on specific changes in gene ex-
pression defined by other lineage-specific regulators. This
agrees with our observation that BAP1 is recruited by
NRF1 and YY1 to both up- and down-regulated genes.
Thus, the pathways regulated by BAP1 that link its loss to
metastasis – as it is in UM tumors – also depend on the
tissue and lineage contexts of the tumor.
Novel BAP1 targets are sufficient to identify aggressive
tumors
The genomic loci identified by the calling card analysis
represent bona fide, biologically valid, physiologically
relevant targets of BAP1. First, genes adjacent to gen-
omic loci targeted by BAP1 show differential expression
when BAP1 is depleted: 70% of genes identified by
calling-card analysis showed BAP1-sensitive expression;
and conversely, 45% of all BAP1-sensitive genes were
adjacent to genomic loci targeted in the calling-card
analysis. Second, the genomic insertions identified by
calling-card analysis clustered as narrow peaks near gene
promoters with motifs known to bind transcription fac-
tors that interact with BAP1. Third, and most important,
the subset of BAP1-responsive, Calling Card genes iden-
tified here are able to discriminate aggressive, class 2 pri-
mary tumor samples from human patients.
Identification of class 2 tumors is vital for clinical
prognosis of the individual patient [27], and loss of
BAP1 expression is seen in > 90% of metastasizing,
class 2 tumors [7]. Comparing our BAP1-responsive,
calling card target genes with the published expres-
sion data from primary UM patient samples [6], we
identified several BAP1 genomic targets that were
able to discriminate between class 1 and class 2 UM
tumors.
Conclusions
We used the calling card methodology to identify the
genomic regions occupied by the chromatin-remodeling
factor, BAP1, despite its inability to bind directly to
DNA. This both expands the possible uses of the calling
card technique to other chromatin-remodeling factors –
as well as transcriptional co-activators and co-repressors
– and identifies for the first time the genomic targets of
BAP1 in UM cells. Far from targeting broad regions of
modified histones, we found that BAP1 interacts with
the genome at narrow regions around transcription start
sites and is targeted to these sites by a specific set of
DNA motifs. We suggest that BAP1 is recruited by
NRF1, YY1, and Ets factors to specific sets of genes that
are co-regulated by other tissue and lineage determi-
nants. Importantly, several BAP1 genomic targets were
able to discriminate aggressive class 2 UM tumors, dem-
onstrating the first functional link between the role of
BAP1 in chromatin remodeling and the phenotypic
switch to metastasizing tumors. Moreover, this link sug-
gests that the class 2 gene expression profile may serve
as a functional readout for loss of BAP1 activity in UM
tumors. Understanding the roles of these class-discrim-
inating BAP1 genomic targets in the broader context of
tumor progression will provide new insights into the cel-
lular mechanisms of UM metastasis.
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Additional file 1: BAP1-PBase genomic peaks. List of genomic regions
of transposon insertion from the BAP1-PBase construct giving location,
number of insertion events (hops), significance, and nearest gene
(Feature). (XLSX 636 kb)
Additional file 2: PBase-BAP1 genomic peaks. List of genomic regions
of transposon insertion from the PBase-BAP1 construct giving location,
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Additional file 3: Immunoblot to confirm knockdown of BAP1.
Immunoblot of protein collected from the three independent experiments
that were used for RNA-seq expressing control or BAP1-specific shRNAs
in OCM-1A cells. Specific bands for BAP1 and GAPDH are indicated.
(PDF 278 kb)
Additional file 4: Table summarizing the RNA-seq results. Differential
gene expression results in BAP1-knockdown compared to control OCM-
1A cells are shown from the RNA-seq data. Each row gives the unique
Ensembl identifier, gene name, and description for each gene, as well as
the log of the fold change (logFC), average expression, adjusted p-value,
and linear fold change. (XLSX 1392 kb)
Additional file 5: BAP1-sensitive calling-card target genes. List of the
784 genes identified by the combination of > 2-fold BAP1-sensitive RNA
expression changes and calling-card transposon targeting. Each row gives
the gene name, unique Ensembl identifier, and description for each gene.
Linear fold change and adjusted p-value in gene expression are from
RNA-seq data. Experimental hops, p-value, and fusion construct data are
from the calling card experiments. (XLSX 135 kb)
Additional file 6: Pathways associated with BAP1 target genes. The ten
most significant pathways associated with BAP1 calling-card target genes
that were up-regulated (positive response) or down-regulated (negative
response) in response to BAP1 depletion. Pathways were identified by
GSEA. (PDF 49 kb)
Additional file 7: GSEA terms associated with BAP1 target genes. Gene
set enrichment analysis based on gene expression values for the 784
genes identified by the combination of > 2-fold BAP1-sensitive RNA
expression changes and calling-card transposon targeting. Each row gives
the name of the curated GSEA term, and the nominal enrichment score,
p-value, false discovery rate (FDR), family-wise error rate (FWER), and rank-
at-max value calculated by the GSEA software. (XLSX 23 kb)
Additional file 8: DNA motifs associated with BAP1 binding. HOMER
was used to identify DNA motifs that were significantly enriched in
genomic regions containing BAP1 calling card insertions. Calling card loci
were divided into three categories based on response of associated
genes to BAP1 depletion, and analyzed separately. (PDF 25 kb)
Additional file 9: Heatmap data. Gene expression values from published
microarray data of primary UM tumors depicted in heatmap in Fig. 5a. Each
row gives the gene rank assigned by comparative marker selection, which
molecular class shows upregulation, and the name of each gene. Signal-to-
noise ratio (SNR), p-values, false discovery rate (FDR), Bonferroni correction,
family-wise error rate (FWER), fold change, means and standard devia-
tions were all calculated by the comparative marker selection soft-
ware. The original expression values from the published data [6] used
to assemble the heatmap are included. (XLSX 196 kb)
Additional file 10: GSEA terms associated with top BAP1 target genes.
Gene set enrichment analysis on the subset of 79 BAP1 targets that were
able to discriminate molecular class in primary tumors. Each row gives
the name of the curated GSEA term, the number of overlapping genes
(size), enrichment score (ES), nominal enrichment score (NES), nominal
p-value, false discovery rate (FDR), family-wise error rate (FWER), and
rank-at-max value calculated by the GSEA software. (XLSX 12 kb)
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